X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ALTO-203 is a novel small molecule histamine H3 receptor inverse agonist, which is being developed for the treatment of patients with MDD and elevated anhedonia.
Lead Product(s): ALTO-203
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-203
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
The net proceeds will be used to advance the clinical development of ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF), which is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $147.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 06, 2024
Details:
The net proceeds will be used to advance the clinical development of ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF), which is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $128.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
The net proceeds will be used to advance the clinical development of ALTO-100, targeting brain-derived-neurotrophic-factor (BDNF) is being developed by Alto Neuroscience for the treatment of major depressive disorder and Post-traumatic stress disorder.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 16, 2024
Details:
ALTO-300 is an investigational small molecule drug candidate, which is a melatonin receptor agonist. currently, it is being evaluated under clinical development with patients suffering related to major depressive disorder.
Lead Product(s): ALTO-300
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-300
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
The funds will be used to support ongoing and planned clinical development of the Company's late-stage CNS product candidates, including ALTO-100 currently in Phase II for Major Depressive Disorder.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: InVivium Capital
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 21, 2023
Details:
The Phase 2 study leveraged Alto’s Precision Psychiatry Platform™ to identify likely drug responders based on an understanding of biological heterogeneity in depression and ALTO-100’s novel mechanism.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Funding will support Alto through a total of four Phase 2 readouts with four novel drug candidates across three indications, as well as the continued evolution of Alto’s Precision Psychiatry Platform™. ALTO-100 is being developed for Major Depressive Disorder.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alpha Wave Ventures
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 30, 2023
Details:
The Phase 2 study leveraged Alto’s Precision Psychiatry Platform™ to identify likely drug responders based on an understanding of biological heterogeneity in depression and ALTO-100’s novel mechanism.
Lead Product(s): ALTO-100
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
Novel drug combinations, ALTO-103 and ALTO-104, exhibited significant pharmacodynamic effects compared to placebo on measures associated with therapeutic response in patients.
Lead Product(s): ALTO-103,ALTO-104,ALTO-102
Therapeutic Area: Psychiatry/Psychology Product Name: ALTO-103
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
